tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Resmed Inc Reports Decrease in CDIs for August 2025

Story Highlights
Resmed Inc Reports Decrease in CDIs for August 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has provided an announcement.

Resmed Inc announced a net decrease in the number of CHESS Depositary Interests (CDIs) issued over quoted securities for August 2025, with a reduction of 4,204,410 CDIs compared to the previous month. This change is attributed to net transfers between CDIs and common stock on the NYSE, as well as activities related to stock options, restricted stock units, employee stock purchase plans, and share repurchases. The announcement reflects the company’s ongoing management of its securities and may impact its market positioning and stakeholder interests.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.25 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

Resmed Inc operates in the healthcare industry, focusing on the development and manufacturing of products for the treatment of sleep disorders, respiratory care, and related medical conditions. The company is known for its innovative solutions in sleep apnea therapy and ventilation support, catering to a global market.

Average Trading Volume: 921,318

Technical Sentiment Signal: Buy

Current Market Cap: A$61.6B

For a thorough assessment of RMD stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1